Overview

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Status:
Completed

Trial end date:
2017-10-20

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, placebo-controlled, multicenter Phase II study to evaluate the safety, efficacy, and pharmacokinetics of ARGX-113 for the treatment of autoimmune Myasthenia Gravis (MG) with generalized muscle weakness.

Phase:

Phase 2

Details

Lead Sponsor:

arGEN-X BVBA
argenx

Collaborator:

Quintiles, Inc.